Halcinonide

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

• Halcinonide cream, USP, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

• Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.contraindicated

Apply the 0.1% halcinonide cream, USP, to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply halcinonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Pregnancy Teratogenic Effects Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General ).

• Nov 27, 1974NDANDA017556Sun Pharm Inds Inc
• May 4, 1977NDANDA017823Sun Pharm Inds Inc
• Aug 12, 2019ANDAANDA211027Mylan
• May 29, 2024ANDAANDA217671Encube

1. 1Drug Ineffective2312%
2. 2Psoriasis199.9%
3. 3Rash168.3%
4. 4Pain136.8%
5. 5Pruritus136.8%
6. 6Arthralgia126.3%
7. 7Diarrhoea105.2%
8. 8Headache105.2%
9. 9Nausea105.2%
10. 10Fatigue94.7%
11. 11Off Label Use94.7%
12. 12Condition Aggravated73.6%
13. 13Depression73.6%
14. 14Weight Decreased73.6%
15. 15Dyspnoea63.1%

Recent PubMed references pinned to Halcinonide as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis.
  Journal of drugs in dermatology : JDD · 2023 · Bagel J, Novak K, Nelson E, et al.
  PMID 37556520DOI 10.36849/jdd.6830
• Response to topical halcinonide following fractional carbon dioxide laser pretreatment in a pretibial myxedema patient.
  Indian journal of dermatology, venereology and leprology · 2018 · Xu Y, Ma R, Cai Y, et al.
  PMID 29363626DOI 10.4103/ijdvl.IJDVL_796_16
• Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation.
  PloS one · 2015 · Porcu G, Serone E, De Nardis V, et al.
  PMID 26658258DOI 10.1371/journal.pone.0144550
• Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
  Cutis · 2015 · Draelos ZD
  PMID 26367752
• Demonstration of the biphasic release of 0.1% halcinonide cream.
  Journal of drugs in dermatology : JDD · 2015 · Draelos ZD
  PMID 25607913
• [Multicenter randomized clinical study of high-intensity focused ultrasound and cortical hormone in the treatment of non-neoplastic epithelial disorders of vulva].
  Zhonghua yi xue za zhi · 2013 · Shi HH, Zhu L, Yang Y, et al.
  PMID 24401626
• Influence of the timing of ultrasound application on the penetration of corticosteroids.
  Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2013 · Clijsen R, Baeyens JP, Barel AO, et al.
  PMID 22712560DOI 10.1111/j.1600-0846.2012.00639.x
• Tropical application of halcinonide cream reduces the severity and incidence of intraperitoneal adhesions in a rat model.
  American journal of surgery · 2002 · Zhang YD, Yao W, Wu CX, et al.
  PMID 12152622DOI 10.1016/s0002-9610(02)00876-0

The 1 most recently updated of 1 ClinicalTrials.gov registrations naming Halcinonide as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
  Recruiting · Phase 4 · Interventional · 25 enrolled · Psoriasis Treatment Center of Central New Jersey
  NCT04347473updated 2020-04-15

Frequently asked questions

How does Halcinonide work?

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists; Lipoxygenase Inhibitors.

What is Halcinonide used for?

According to FDA labeling, Halcinonide carries indications including: Halcinonide cream, USP, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Halcinonide?

Halcinonide is classified as Corticosteroids, very potent (group IV), Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Lipoxygenase Inhibitors, Antipruritic Activity, Decreased Immunologically Active Molecule Activity, Decreased Protein Synthesis, Vasoconstriction.

What are the brand names for Halcinonide?

Halcinonide is marketed under brand names including Halog.

What are the contraindications for Halcinonide?

Halcinonide labeling lists contraindications including: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.. Always consult the full prescribing information and a clinician.